Jun 29 2023
June, 2023 Quick Question Review
Our June 2023 Quick Question asked, “Name the bispecific antibody-based FVIII inhibitor bypass agent.” Our 68 respondents answered… Caplacizumab [Cablivi]: 3 [4%] Eculizumab [Soliris]: 8 [12%] Emicizumab [Hemlibra]: 53 [78%] Eloctate: 3 [4%] Jivi: 1 [2%] Genentech’s emicizumab is the bispecific antibody that bypassed FVIII in to join FIX to FX, activating FX. Emicizumab is […]
read more